Altimmune's (ALT) Three Liver Trials Move Forward At Once
On August 12, Altimmune (NASDAQ:ALT) reported second quarter results that read less like a routine earnings update and more like a status check on three separate diseases at the same time.
Altimmune Inc. (ALT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 19,250,000 | $58,520,000 | 0.85% | |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 6,841,055 | $20,796,808 | +71% | 0.02% |
| 3. | Viking Global Andreas Halvorsen | 6,700,000 | $20,368,000 | 0.06% | |
| 4. | RA Capital Management Peter Kolchinsky | 6,500,000 | $19,760,000 | 0.17% | |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,400,312 | $10,336,948 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.95 | 15,000 | $44,250.00 | 62,500 | 2026-08-13 | Filing | |
| $3.41 | 9,200 | $31,349.92 | 21,700 | 2026-04-06 | Filing | |
| $3.15 | 10,000 | $31,499.00 | 38,078 | 2026-04-01 | Filing | |
| $3.14 | 15,000 | $47,100.00 | 47,500 | 2026-04-01 | Filing | |
| $3.54 | 5,000 | $17,700.00 | 28,078 | 2026-03-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.88 | 8,184 | $56,305.92 | 55,524 | 2024-08-19 | Filing | |
| $6.93 | 7,827 | $54,241.11 | 41,958 | 2024-08-19 | Filing | |
| $15.00 | 2,714 | $40,710.00 | 2,771 | 2022-08-12 | Filing | |
| $15.01 | 20,000 | $300,268.00 | 8,498 | 2022-12-22 | Filing | |
| $20.02 | 20,000 | $400,322.00 | 236,797 | 2022-08-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 744,997 | $2,130,691 | 0.06% | |
| 2. | 421,858 | $1,206,514 | 0.24% | |
| 3. | 240,136 | $686,789 | 0.15% | |
| 4. | 125,950 | $360,217 | 0.1% | |
| 5. | 103,288 | $295,404 | 0.04% |
News See All
3 Under $10 Stocks With 150%+ Upside to Buy in September 2026, According to Analysts
Some low‑priced stocks have the potential to offer solid upside backed by clear catalysts. In September, three names under $10 stand out for strong...
10 Overlooked Penny Stocks to Buy Right Now
In this piece, we will discuss the 10 Overlooked Penny Stocks to Buy Right Now.
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Altimmune, Inc. (NASDAQ:ALT) is one of the best weight loss drugs on this list. TheFly reported on May 18 that H.C.
10 Best Weight Loss Drug Stocks to Buy in 2026
In this article, we will be taking a look at the 10 Best Weight Loss Drug Stocks to Buy in 2026. The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.
10 Small Cap Stocks with Potential to Rise 1000 Percent
In this article, we look at 10 Small Cap Stocks with Potential to Rise 1000 Percent. Small-cap stocks have returned to the market’s risk conversation in 2026.
Altimmune, Inc. (NASDAQ:ALT) Q1 2026 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT) Q1 2026 Earnings Call Transcript May 13, 2026Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.25.
10 Most Shorted Penny Stocks to Buy
In this article, we will take a look at some of the most shorted penny stocks that currently appear highly attractive with impressive upside potential.
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases
Altimmune, Inc. (NASDAQ:ALT) earns a spot on our list of the top 10 stocks under $5 that could triple. On March 16, 2026, H.C.
Top 10 Stocks Under $5 That Could Triple
In this piece, we discuss the Top 10 Stocks Under $5 That Could Triple.
Hedge Fund Resource Center